Myriad Genetics, Inc.

NasdaqGS:MYGN Voorraadrapport

Marktkapitalisatie: US$2.4b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Myriad Genetics Beheer

Beheer criteriumcontroles 2/4

De CEO Myriad Genetics' is Paul Diaz, benoemd in Aug2020, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.11M, bestaande uit 9% salaris en 91% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.46% van de aandelen van het bedrijf, ter waarde $ 11.36M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 4.7 jaar.

Belangrijke informatie

Paul Diaz

Algemeen directeur

US$12.1m

Totale compensatie

Percentage CEO-salaris9.0%
Dienstverband CEO4.2yrs
Eigendom CEO0.5%
Management gemiddelde ambtstermijn2.3yrs
Gemiddelde ambtstermijn bestuur4.7yrs

Recente managementupdates

Recent updates

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Sep 20
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Aug 30
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

Jul 17
Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Jun 05
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18
Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Aug 07
Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Apr 13
Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Myriad: Trying To Find Its Footing In An Evolving Industry

Sep 26

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Aug 25

Analyse CEO-vergoeding

Hoe is Paul Diaz's beloning veranderd ten opzichte van Myriad Genetics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$155m

Mar 31 2024n/an/a

-US$235m

Dec 31 2023US$12mUS$1m

-US$263m

Sep 30 2023n/an/a

-US$274m

Jun 30 2023n/an/a

-US$248m

Mar 31 2023n/an/a

-US$146m

Dec 31 2022US$11mUS$1m

-US$112m

Sep 30 2022n/an/a

-US$77m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$8m

Dec 31 2021US$13mUS$1m

-US$27m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$97m

Mar 31 2021n/an/a

-US$148m

Dec 31 2020US$16mUS$383k

-US$224m

Compensatie versus markt: De totale vergoeding ($USD 12.11M ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).

Compensatie versus inkomsten: De vergoeding van Paul is gestegen terwijl het bedrijf verliesgevend is.

CEO

Paul Diaz (62 yo)

4.2yrs

Tenure

US$12,108,359

Compensatie

Mr. Paul J. Diaz serves as the Member of Advisory Board at Thornton Capital, LLC. He has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He serves a...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Paul Diaz
CEO, President & Director4.2yrsUS$12.11m0.46%
$ 11.0m
Samraat Raha
Chief Operating Officerless than a yearUS$5.02mgeen gegevens
Dale Muzzey
Chief Scientific Officer2.8yrsUS$2.23m0.12%
$ 2.9m
Mark Verratti
Chief Commercial Officer7.2yrsUS$2.88m0.33%
$ 7.9m
Scott Leffler
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Natalie Munk
Principal Accounting Officer2.3yrsgeen gegevens0.048%
$ 1.1m
Kevin Haas
Chief Technology Officer3.7yrsUS$1.64m0.15%
$ 3.5m
Matthew Scalo
Senior Vice President of Investor Relationsno datageen gegevensgeen gegevens
Jennifer Fox
Chief Legal Officerless than a yeargeen gegevensgeen gegevens
Glenn Farrell
Senior VP & Chief Marketing Officer1.8yrsgeen gegevensgeen gegevens
Shereen Solaiman
Chief People Officer1.6yrsgeen gegevens0.0031%
$ 75.5k
Patrick Burke
Executive Vice President of Strategy & Innovation3.4yrsgeen gegevensgeen gegevens

2.3yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MYGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Paul Diaz
CEO, President & Director4.2yrsUS$12.11m0.46%
$ 11.0m
Paul Bisaro
Independent Director2yrsUS$258.48k0.027%
$ 647.2k
Lee Newcomer
Independent Director5.1yrsUS$447.99k0.073%
$ 1.8m
Daniel Skovronsky
Independent Director4.3yrsUS$433.49k0.077%
$ 1.9m
Colleen Reitan
Independent Director5.1yrsUS$443.49k0.030%
$ 710.4k
Heinrich Dreismann
Independent Director14.3yrsUS$443.49k0.12%
$ 2.8m
S. Phanstiel
Independent Chair of the Board15.1yrsUS$563.49k0.16%
$ 3.8m
Rashmi Kumar
Independent Director4.1yrsUS$433.49k0.068%
$ 1.6m

4.7yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MYGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).